M&A outbreak set to continue, says PwC
This article was originally published in Scrip
Deal value in the first quarter of 2014 increased by 123% compared with the same period last year, according to the never timelier Pharmaceutical and Life Sciences Deals Insights Quarterly report from PwC. As the industry struggles to catch its breath with almost daily major M&A breaking news, PwC's sector overview outlines some key deal statistics and drivers of recent months.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.